BOTOX® (botulinum toxin type A) Chronic Migraine Abbreviated Prescribing Information

Presentation: Botulinum toxin type A (from clostridium botulinum), 50 or 100 or 200 Allergan Units/vial. **Indications:** Prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). **Dosage and Administration:** See Summary of Product Characteristics for full information. Reconstitute with sterile unpreserved normal saline (0.9% sodium chloride for injection). Botulinum toxin units are not interchangeable from one product to another. If different vial sizes of BOTOX are being used as part of one injection procedure, care should be taken to use the correct amount of diluent when reconstituting a particular number of units per 0.1 ml. The amount of diluent varies between BOTOX 50 Allergan Units, BOTOX 100 Allergan Units and BOTOX 200 Allergan Units. Each syringe should be labeled accordingly. In the event of treatment failure or diminished effect following repeat injections alternative treatment methods should be employed. Inject using 30 gauge, 0.5 inch needle, or 1 inch needle for thicker muscles in neck region if required. Inject 0.1ml (5 Units) intramuscularly to 31 (up to 39) injection sites, divided across seven specific head/neck muscle areas including frontalis, corrugator, procerus, occipitalis, temporalis, trapezius and cervical paraspinal muscles. Inject bilaterally, with the exception of procerus. Total dose 155 Units – 195 Units. **Contra-indications:** Known hypersensitivity to any constituent. Pregnancy or lactation. Presence of infection at proposed injection site(s). **Warnings/Precautions**: The recommended dosages and frequencies of administration of BOTOX should not be exceeded due to the potential for overdose, exaggerated muscle weakness, distant spread of toxin and the formation of neutralizing antibodies. Initial dosing in treatment naive patients should begin with the lowest recommended dose for the specific indication. Prescribers and patients should be aware that side effects can occur despite previous injections being well tolerated. Caution should be exercised on the occasion of each administration. Reports of side effects related to spread of toxin distant from injection site, sometimes resulting in death. The risk of symptoms is probably greatest in patients who have underlying conditions and comorbidities, including children and adults treated for spasticity, and are treated with high doses. Elderly and debilitated patients should be treated with caution. Dysphagia has also been reported following injection to sites other than the cervical musculature. BOTOX should only be used with extreme caution and under close supervision in patients with subclinical or clinical evidence of defective neuromuscular transmission and in patients with underlying neurological disorders. Caution in patients with underlying neurological disorder and history of dysphagia and aspiration. Patients should seek medical help if swallowing, speech or respiratory disorders arise. Previously sedentary patients should resume activities gradually. Relevant anatomy and changes due to prior surgical procedures must be understood prior to administration and injection into vulnerable anatomic structures must be avoided. Pneumothorax associated with injection procedure has been reported. Caution is warranted when injecting in proximity to the lung, particularly the apices or other vulnerable structures. Serious adverse events including fatal outcomes have been reported in patients who had received off-label injections directly into salivary glands, the oro-lingual-pharyngeal region, oesophagus and stomach. If serious and/or immediate hypersensitivity reactions occur (in rare cases), injection of toxin should be discontinued and appropriate medical therapy, such as epinephrine, immediately instituted. Procedure related injury could occur. Caution in the presence of inflammation at injection site(s) or when excessive weakness/atrophy is present in target muscle. Reports of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. New onset or recurrent seizure occurred rarely in predisposed patients, however relationship to botulinum toxin has not been established. Clinical fluctuations may occur during repeated use. Too frequent or excessive dosing can lead to antibody formation and treatment resistance. Efficacy has not been shown in prophylaxis of episodic migraine (headaches <15 days per month). May cause asthenia, muscle weakness, somnolence, dizziness and visual disturbance which could affect driving and operation of machinery. **Interactions:** Theoretically, effect may be potentiated by aminoglycoside antibiotics or other drugs that interfere with neuromuscular transmission. **Adverse Effects:** See Summary of Product Characteristics for full information on side effects including details of uncommon, rare and very rare events. *General:* Usually occur within the first few days following injection and are transient, but rarely persist for several months or longer. Local muscle weakness represents the expected pharmacological action. Localised pain, tenderness and/or bruising may be associated with the injection. Fever and flu syndrome have been reported. *Frequency defined as follows*: Common (≥1/100 to <1/10): Headache, migraine, facial paresis, eyelid ptosis, pruritus, rash, neck pain, myalgia, musculoskeletal pain, musculoskeletal stiffness, muscle spasms, muscle tightness, muscular weakness, injection site pain. Please refer to the Summary of Product Characteristics for further information including adverse events that have been reported since the drug has been marketed. **Basic NHS Price:** 50 Units: £77.50, 100 Units: £138.20, 200 Units £276.40 **Marketing Authorisation Number:** 50 Units: 426/0118, 100 Units: 426/0074, 200 Units 426/0119. **Marketing Authorisation Holder:** Allergan Ltd, Marlow International, The Parkway, Marlow, Bucks, SL7 1YL, UK. **Legal Category:** POM. **Date of preparation:** August 2013.

Further information is available from: Allergan Limited, Marlow International, The Parkway, Marlow, Bucks SL7 1YL

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Allergan Ltd. UK_Medinfo@allergan.com or 01628 494026.